Ph Interfering Agents As Chemosensitizers In Cancer Therapy

pH Interfering Agents as Chemosensitizers In Cancer Therapy, Volume Thirteen, provides a detailed overview of the chemosensitizers for the treatment of cancer spanning from biochemical and structural features to pharmacology and drug-design, including technological applications. The book is structured with innovative outlines and a distinction between experimental and clinical results. The continuous discovery and assessment of the role played by old/new synthetic drugs, natural compounds and technological applications has led to the urgent need of classification in terms of biological activity, mechanism of action, clinical outcomes, cancer cell lines sensible to the treatment, and potentialities to better orient research in this field. Moreover, all the aspects relevant for medicinal chemistry (drug design, structure-activity relationships, permeability data, cytotoxicity, appropriate statistical procedures, and molecular modeling studies) are strictly considered. Presents a broad view of the topic according to a medicinal chemistry-based approach beyond syntheses and biological assays, focusing on SAR studies, chemoinformatic, drug targeting and molecular modeling Explains the mechanism of action of the chemosensitizers by means of schemes and figures to facilitate comprehension Discusses novel targets to explore new possibilities that enhance research in the field

Introduction and basic concepts of cancer / Devivasha Bordoloi, Bethsebie Lalduhsaki Sailo, Nafiseh Mantegh, Ganesan Padmavathi, Ajaikumar B. Kunnumakkara -- Cancer cell chemoresistance : a prime obstacle in cancer therapy -- Javadi Monisha [and 6 others] -- Bladder cancer : chemoresistance and chemosensitization / Nand Kishor Roy, Anand Sharma, Anuj Kumar Singh, Devivasha Bordoloi, Ajaikumar B. Kunnumakkara -- Mechanism of chemoresistance in bone cancer and different chemosensitization approaches / Ganesan Padmavathi, Devivasha Bordoloi, Kishore Banik, Anuj Kumar Singh, Ajaikumar B. Kunnumakkara -- Chemoresistance in brain cancer and different chemosensitization approaches / Amrita Devi Khwairakpam [and 6 others] -- Phytochemicals as chemosensitizers in breast cancer / Madhumita Roy, Ruma Sarkar, Apurba Mukherjee, Sutapa Mukherjee & Jaydip Biswas -- Potential of different chemosensitizers to overcome chemoresistance in cervical cancer / Kishore Banik [and 5 others] -- Colon cancer chemoresistance and chemosensitization / Muthu K. Shanmugam, Arunasalam Dharmarajan, Frank Arfuso, Gautam Sethi -- Cancer cell chemoresistance and chemosensitization in endometrial cancer / Anuj Kumar Singh [and 5 others] -- Different approaches to overcome chemoresistance in esophageal cancer / Devivasha Bordoloi [and 5 others] -- Different chemosensitization approaches in gastric cancer / Choudhary Harsha [and 5 others] -- Chemoresistance and chemosensitization in haematological malignancies / Ota Fuchs -- Different methods to inhibit chemosresistance in hepatocellular carcinoma / Anuj Kumar Singh [and 6 others] -- Different chemosensitization approaches for the effective management of HNSCC / Krishan K. Thakur, Devivasha Bordoloi, Jai Prakash, Nand Kishor Roy, Ajaikumar B. Kunnumakkara -- Lung cancer chemoresistance and chemosensitization / Kenneth K.W. To -- Sensitization of chemoresistant melanoma cells to different chemotherapeutic agents / Javadi Monisha [and 5 others] -- Strategies to overcome chemoresistance in ovarian cancer / Choudhary Harsha [and 5 others] -- Molecular alterations involved in pancreatic cancer chemoresistance and chemosensitization strategies / Bethsebie Lalduhsaki Sailo [and 8 others] -- Different chemosensitization approaches to overcome chemoresistance in prostate cancer / Ganesan Padmavathi [and 6 others] -- Therapeutic strategies for chemosensitization of renal cancer / Bethsebie Lalduhsaki Sailo, Devivasha Bordoloi, Kishore Banik, Jai Prakash, Ajaikumar B. Kunnumakkara.

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field. Provides the most updated reviews on anti-angiogenic drugs as chemosensitizers by leaders in the field Encompasses summarized tables and schematic diagrams in each chapter to give a clear overview on recent findings in a didactic manner Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field

Prostate cancer (PCa) is among the most diagnosed cancers in men worldwide as well as one of the most common causes of cancer-related deaths. Despite the advances in treatment, the disease remains associated with poor survival and resistance to cytotoxic and targeted therapies. Therapy Resistance in Prostate Cancer: Mechanisms and Insights highlights the main mechanisms that are responsible for therapy resistance in PCa allowing researchers and clinicians to have a synopsis of current options and new therapies that can be proposed to overcome this resistance. Understanding the mechanisms responsible for chemotherapy resistance helps researchers all over the world to delve deeper into the pathways behind this resistance and potentially discover new therapeutic targets for PCa. Tackles the topic of resistance from a broader perspective, including, but not limited to, the role of the extracellular matrix and cancer stem cells in therapy resistance Creates understanding on how to develop novel therapies that specifically target CSCs to eliminate the regenerating capacity of the tumor and overcome therapy resistance Helps in identifying novel molecular biomarkers and potential therapeutic targets pertaining to the tumor microenvironment to overcome therapy resistance Provides a general view of the main pathways involved in PCa progression that will aid in understanding the mechanisms responsible for chemotherapy resistance

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment. Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality Presents an overview of current treatments and the benefits of ALK TKI in lung and other cancer types, such as ALCL, neuroblastoma and inflammatory myofibroblastic tumor Encompasses information on systemic treatments other than TKI, including chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC

Strategies for overcoming chemotherapy resistance in cervical cancer highlights different strategies to reverse chemotherapy resistance in cervical cancer. The book has a strong focus on strategies to reverse chemotherapy resistance as well as strategies for early detection of the resistance, enhancing precision oncology in terms of patient care and maximizing patient management. The book also looks at virally induced resistance to chemotherapy and recommends combination therapies that can maximize the reversal of this resistance. In 10 chapters Strategies for overcoming chemotherapy resistance in cervical cancer not only gives an overview of cervical cancer and chemotherapy as treatment, but it also investigates resistance to chemotherapy and the treatment for resistance. It defines the treatment mechanisms, options, and limitations to beat chemotherapy resistance and the reversal of the resistance mechanisms. It gives insights into the future directions of cervical cancer treatment using epigenetic silencing, chemotherapy splicing, the involvement of MicroRNAs to chemotherapy resistance, and the application of Artificial Intelligence. This book is a valuable resource for health professionals, scientists and researchers, oncologists, virologists, health practitioners, medical and graduate students, and all those who wish to broaden their knowledge in the allied field. Discusses strategies to reverse and detect resistance to chemotherapy at an early stage Investigates the applications of Artificial Intelligence in the study of cervical chemotherapy resistance Presents research and applications developed to overcome cancer resistance

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges. Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies